Sciele Pharma, Inc. Announces FDA Acceptance of NDA for Summers Laboratories' Head Lice Treatment

ATLANTA--(BUSINESS WIRE)--Sciele Pharma, Inc. (NASDAQ:SCRX) today announced that the U.S. Food & Drug Administration (FDA) has accepted the New Drug Application (NDA) submitted by Summers Laboratories for a head lice asphyxiation product that utilizes a novel mechanism of action. Sciele acquired the rights to this product for the United States, Canada, and Mexico, and Summers submitted its NDA for this patented treatment on June 15, 2007.